Teleflex (NYSE:TFX) Cut to Buy at Wall Street Zen

Key Points

• Teleflex has been downgraded by Wall Street Zen from a "strong-buy" to a "buy" rating.
• Wells Fargo reduced its target price for Teleflex from $137.00 to $131.00, while both Royal Bank of Canada and Mizuho increased theirs to $135.00.
• In the last quarter, Teleflex reported $3.73 earnings per share, exceeding expectations and signifying a 4.2% revenue increase compared to the prior year.

Teleflex (NYSE:TFX - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report issued on Monday.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their target price on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. Royal Bank Of Canada increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research report on Friday, August 1st. Finally, Mizuho increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $141.57.

Teleflex Stock Down 1.5%

Shares of NYSE TFX opened at $130.47 on Monday. The firm's 50-day moving average price is $120.97 and its 200-day moving average price is $125.99. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $5.77 billion, a price-to-earnings ratio of 30.70, a P/E/G ratio of 1.82 and a beta of 1.08. Teleflex has a 12-month low of $108.90 and a 12-month high of $249.90.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.36 by $0.37. The firm had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business's revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, equities research analysts anticipate that Teleflex will post 13.98 EPS for the current fiscal year.

Insider Buying and Selling at Teleflex

In related news, Director Stuart A. Randle bought 1,000 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average cost of $115.86 per share, with a total value of $115,860.00. Following the completion of the transaction, the director owned 7,547 shares in the company, valued at $874,395.42. The trade was a 15.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gretchen R. Haggerty bought 500 shares of Teleflex stock in a transaction dated Wednesday, August 6th. The shares were bought at an average cost of $114.75 per share, for a total transaction of $57,375.00. Following the completion of the transaction, the director owned 6,305 shares of the company's stock, valued at approximately $723,498.75. This trade represents a 8.61% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 5,500 shares of company stock valued at $633,590. 1.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teleflex

A number of institutional investors have recently modified their holdings of TFX. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Teleflex by 242.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock worth $26,000 after acquiring an additional 153 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 103.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 100 shares in the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Teleflex during the first quarter valued at approximately $27,000. Costello Asset Management INC bought a new position in shares of Teleflex during the first quarter valued at approximately $28,000. Finally, Brooklyn Investment Group boosted its stake in shares of Teleflex by 258.6% during the first quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 150 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.